Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 11th Nov 2013 08:50

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p.Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation.British Land: Deutsche Bank downgrades to sell with a target price of 520p.British Sky Broadcasting: Nomura reduces target price from 1040p to 850p and downgrades from buy to reduce. Goldman Sachs cuts target price from 1120p to 1070p, while reiterating its buy recommendation.BT Group: JP Morgan increases target price from 380p to 420p upgrading from neutral to overweight. Citi ups target price from 400p to 430p retaining a buy recommendation. UBS cuts target price from 310p to 290p and stays with its sell recommendation.Cable & Wireless Communications: Jefferies shifts target price from 45p to 48p and retains a hold recommendation.Carr's Milling: Investec places both its target price (prev.: 1710p) and its buy recommendation under review.Cobham: Investec cuts target price from 275p to 230p retaining its sell recommendation.Dignity: Investec raises target price from 1562p to 1583p and upgrades from add to buy.Faroe Petroleum: Panmure Gordon moves target price from 182p to 188p and retains a buy recommendation. Westhouse Securities shifts target price from 175p to 185p and maintains a buy recommendation.FlyBe: Liberum Capital initiates with a target price of 90p and a buy recommendation.Gemfields: Investec moves target price from 30p to 37.5p and reiterates a buy recommendation.International Consolidated Airlines Group: Citi raises target price from 380p to 535p and stays with its buy recommendation. HSBC takes target price from 405p to 420p maintaining an overweight rating. Credit Suisse increases target price from 345p to 443p and reiterates an outperform rating.International Personal Finance: RBC Capital shifts target price from 700p to 695p and maintains an outperform rating.ITV: Citi ups target price from 180p to 191p, while downgrading from buy to neutral. Goldman Sachs lowers target price from 240p to 237p and retains a buy recommendation.Lonmin: Investec places its target price (prev.: 266p), while leaving its sell recommendation unaltered.Morgan Advanced Materials: Investec places its target price (prev.: 410p) under review, while keeping its buy recommendation.Paragon Group: RBC Capital ups target price from 350p to 390p upgrading to outperform.Rentokil Initial: JP Morgan moves target price from 75p to 86p, while leaving its underweight rating unchanged.Royal Bank of Scotland: Jefferies raises target price from 390p to 441p and keeps a buy recommendation.RSA Insurance Group: Citi reduces target price from 146p to 126p downgrading from buy to neutral. Panmure Gordon moves target price from 98p to 117p, but still recommends selling. Credit Suisse lowers target price from 125p to 110p and downgrades to underperform.Shire: Panmure Gordon raises target price from 2850p to 3100p and keeps a buy recommendation.Tullett Prebon: UBS cuts target price from 315p to 290p and maintains its sell recommendation.Verona Pharma: N+1 Singer initiates with a target price of 5.1p and a buy recommendation.Wincanton: Investec ups target price from 75p to 122p, while downgrading from buy to hold.
More News
9 Jun 2015 14:36

AGM, EGM Calendar - Week Ahead

Read more
9 Jun 2015 05:28

AGM, EGM Calendar - Week Ahead

Read more
8 Jun 2015 14:56

AGM, EGM Calendar - Week Ahead

Read more
8 Jun 2015 06:49

Verona Pharma Says Study Shows RPL554 Well Tolerated

Read more
8 Jun 2015 05:33

AGM, EGM Calendar - Week Ahead

Read more
5 Jun 2015 15:03

AGM, EGM Calendar - Week Ahead

Read more
5 Jun 2015 05:21

AGM, EGM Calendar - Week Ahead

Read more
4 Jun 2015 15:22

AGM, EGM Calendar - Week Ahead

Read more
22 May 2015 13:01

DIRECTOR DEALINGS SUMMARY: Glencore Non-Executive Cuts Stake

Read more
18 May 2015 14:03

DIRECTOR DEALINGS: Verona Pharma Directors Buy Shares

Read more
12 May 2015 16:22

Verona Pharma's loss widens on extended development costs

Verona Pharma posted a widened pre-tax loss for 2014 in the run up to its lead compound's commercial development. The company posted a pre-tax loss of £3.8m for 2014, up from £2.8m a year earlier, as research costs swelled from £1.7m to £2.6m over the period. Development bore a new commercial formu

Read more
12 May 2015 10:30

Verona Loss Widens As It Continues Lead Compound Development

Read more
12 May 2015 05:18

Earnings, Trading Statements Calendar - Week Ahead

Read more
11 May 2015 14:56

Earnings, Trading Statements Calendar - Week Ahead

Read more
11 May 2015 05:34

Earnings, Trading Statements Calendar - Week Ahead

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.